Leptin and resistin levels in serum of patients with hematologic malignancies: correlation with clinical characteristic

Aim:To evaluate leptin and resistin levels in patients with various hematologic malignancies. Methods: We included 21 patients with lymphoma, 14 with multiple myeloma (MM), 14 with acute leukemia, 13 with chronic lymphocytic leukemia (CLL), and 25 healthy control subjects into our study. The subjects’ body mass indexes (BMI) were calculated; hematological and acute phase response parameters, serum lipid were determined; serum leptin and resistin levels were determined by ELISA. Results: Serum leptin level was significantly increased in CLL and MM groups when compared to the control group (p < 0.01). Resistin level was significantly higher in lymphoma patients than in CLL, acute leukemia and control groups (p < 0.01). In the control group, leptin level was negatively correlated with hemoglobin level (r = –0.44, p = 0.047); and in all patients with hematologic malignancies, leptin level was correlated with BMI (r = 0.32, p = 0.02). Leptin in lymphoma subjects correlated with hemoglobin level (r = 0.64, p = 0.005), resistin level correlated with the platelet count in patients with hematologic malignancies (r = 0.26, p = 0.044). In addition, leptin level had negative correlations with international prognostic score (IPS) in Hodgkin lymphoma (r = –0.9, p = 0.002) and with international prognostic index (IPI) in non-Hodgkin lymphoma (r = –0.77, p = 0.03). In CLL patients, leptin level had a correlation with the poor prognostic marker — CD38 level (r = 0.68, p = 0.03). Conclusion: We found higher leptin levels in MM and CLL patients, and higher resistin levels in lymphoma patients: this fact demonstrates that changes in adipose tissue and metabolism occur in these disease states.Цель: определить уровни содержания лептина и резистина в сыворотке крови больных с различными онкогематологическими заболеваниями. Методы: обследован 21 больной лимфомой, 14 — множественной миеломой (ММ), 14 — острой лейкемией, 13 — хронической лимфоцитарной лейкемией (ХЛЛ), и 25 здоровых доноров. У пациентов определены такие характеристики: индекс массы тела (ИМТ), гематологические параметры, содержание липидов в сыворотке крови. Содержание лептина и резистина в сыворотке крови определяли иммуноферментным методом. Результаты: уровень лептина в сыворотке крови был значительно выше у больных с ХЛЛ и ММ, чем таковой у контрольной группы (р < 0,01). Уровень резистина был значительно выше в группе больных с лимфомами по сравнению с ХЛЛ, острой лейкемией и контрольной группами (р < 0,01). В контрольной группе уровень лептина отрицательно коррелировал с уровнем гемоглобина (r = –0,44, р = 0,047), а во всех группах больных уровень лептина коррелировал с ИМТ (r = 0,32, р = 0,02). Уровень лептина при лимфомах коррелировал с уровнем гемоглобина (r = 0,64, р = 0,005), уровень резистина коррелировал с количеством тромбоцитов у больных всех групп (r = 0,26, р = 0,044). При лимфоме Ходжкина выявлена отрицательная корреляция между уровнем лептина и величиной международной прогностической шкалы (r = -0,9, р = 0,002), при неходжкинской лимфоме — величиной международного прогностического индекса (r = –0,77, р = 0,03), у больных ХЛЛ — с уровнем экспрессии CD38 (r = 0,68, р = 0,03). Выводы: у больных ММ и ХЛЛ выявлен высокий уровень лептина, а с лимфомами — высокий уровень резистина: этот факт указывает на то, что у больных указанными онкогематологическими заболеваниями могут возникать изменения в структуре жировой ткани и обмене веществ

The efficacy of sequential therapy in eradication of Helicobacter pylori in Turkey

Background and Aim: Most of the studies about sequential therapy that have been reported from Turkey were levofloxacin based. We aimed to compare the Helicobacter pylori (H. pylori) eradication rates of standard triple, sequential and quadruple therapies including claritromycin regimes in this study. Materials and Methods: A total of 160 patients with dyspeptic symptoms were enrolled to the study. The patients were randomized to four groups of treatment protocols. And 40 patients received standard triple therapy for 2 weeks, 40 patients received bismuth containing quadruple therapy for 2 weeks, 40 patients received 5 + 5 clarithromycin-based sequential therapy, and 40 patients received 7 + 7 clarithromycin-based sequential therapy. H. pylori eradication was assessed by C 14 urea breath test 4 weeks after therapy. Results: Out of 160 patients with H. pylori infection, 131 (81.9%) were eradicated successfully and 29 (18.1%) failed to eradicate H. pylori infection. H. pylori eradication was achieved in 28 of 40 patients receiving standard triple therapy (70%), in 33 of 40 patients receiving quadruple therapy (82.5%), in 37 of 40 patients receiving 5 + 5 sequential therapy (92.5%), and in 33 of 40 patients receiving 7 + 7 sequential therapy (82. 5%). Statistics revealed that 5 + 5 sequential therapy led to significantly higher H. pylori eradication rates compared with that of standard triple therapy (P = 0.019). There was no statically difference between 5 + 5 sequential therapy and the other therapy groups' eradication rates, but it was higher than all of the protocols. H. pylori eradication rate with sequential therapy in our patients with nonulcer dyspepsia was higher than those of patients with standard therapy (93% versus 82%, respectively, P>0.05). Conclusion: 5 + 5 sequential therapy was associated with significantly higher eradication rate of H. pylori compared with standard triple therapy in our study cohort. © 2017 Nigerian Journal of Clinical Practice

The efficacy of sequential therapy in eradication of Helicobacter pylori in Turkey

Background and Aim: Most of the studies about sequential therapy that have been reported from Turkey were levofloxacin based. We aimed to compare the Helicobacter pylori (H. pylori) eradication rates of standard triple, sequential and quadruple therapies including claritromycin regimes in this study.Materials and Methods: A total of 160 patients with dyspeptic symptoms were enrolled to the study. The patients were randomized to four groups of treatment protocols. And 40 patients received standard triple therapy for 2 weeks, 40 patients received bismuth containing quadruple therapy for 2 weeks, 40 patients received 5 + 5 clarithromycin-based sequential therapy, and 40 patients received 7 + 7 clarithromycin-based sequential therapy. H. pylori eradication was assessed by C 14 urea breath test 4 weeks after therapy.Results: Out of 160 patients with H. pylori infection, 131 (81.9%) were eradicated successfully and 29 (18.1%) failed to eradicate H. pylori infection. H. pylori eradication was achieved in 28 of 40 patients receiving standard triple therapy (70%), in 33 of 40 patients receiving quadruple therapy (82.5%), in 37 of 40 patients receiving 5 + 5 sequential therapy (92.5%), and in 33 of 40 patients receiving 7 + 7 sequential therapy (82. 5%). Statistics revealed that 5 + 5 sequential therapy led to significantly higher H. pylori eradication rates compared with that of standard triple therapy (P = 0.019). There was no statically difference between 5 + 5 sequential therapy and the other therapy groups’ eradication rates, but it was higher than all of the protocols. H. pylori eradication rate with sequential therapy in our patients with nonulcer dyspepsia was higher than those of patients with standard therapy (93% versus 82%, respectively, P&gt;0.05).Conclusion: 5 + 5 sequential therapy was associated with significantly higher eradication rate of H. pylori compared with standard triple therapy in our study cohort.Keywords: H.pylori, sequential therapy, eradication protocol

A case of cervical spine meningioma following etanercept use in a patient with RA

Background. A 70-year-old female with active rheumatoid arthritis (RA) was administered etanercept to treat active disease that persisted despite therapy with conventional DMARDs. After 18 months of etanercept therapy, her RA symptoms had improved; however, she developed quadriparesis. She presented to a specialist rheumatology clinic with weakness and numbness in her arms and legs; she also had difficulty in standing up and walking. Investigations. Physical examination, neurological examination, nerve conduction studies, measurement of serum inflammatory markers and autoantibodies, MRI of the cranium and cervical spine, and X-rays of the chest and hands. Diagnosis. The patient underwent neurosurgery to resect a 1 × 2 cm mass in the cervical spine at C6–C7. Histopathologic examination of the excised mass revealed it to be a meningioma. Management. Etanercept was discontinued because of a possible association between the drug and development of meningioma; however, shortly afterwards the patient experienced a flare of RA symptoms. High-dose NSAIDs and prednisolone were administered, but the patient died because of gastric perforation. To our knowledge, this is the first report in the literature of meningioma developing following use of tumor necrosis factor inhibitor therapy, and the first to suggest a cause–effect relationship. © 2009 Macmillan Publishers Limited. All rights reserved

Novel triazole containing zinc(II)phthalocyanine Schiff bases: Determination of photophysical and photochemical properties for photodynamic cancer therapy

A simple and efficient synthesis of novel zinc(II) phthalocyanines bearing triazole moieties was described. The synthetic approach for preparation of the phthalocyanines 1 and 13 was achieved by Schiff base condensation reaction of phthalocyanine tetracarbaldehydes 3 and 12 with 4-amino-4H-1,2,4-triazole 5 in tetrahydrofuran in reasonable yields. The photophysical and photochemical properties of the compounds 1, 3, 12 and 13 were recorded only in DMSO. The singlet oxygen generation ability of the targeted phthalocyanine Schiff bases were investigated in an attempt to understand their potential for photodynamic therapy (PDT) activity. Moreover, in vitro PDT application was performed against the MCF-7 and MDA-MB-231 invasive breast carcinoma cell lines. Preliminary assay showed that the compounds 1 and 13 possessed the phototoxicity and cytotoxicity, with a maximum of 30% MCF-7 cells dead following light irradiation. It was also revealed that the targeted phthalocyanines possess promising characteristic as photosensitizer towards tumor cells